Home › Companies › KPRX

Kiora Pharmaceuticals

Market cap $4.1M 4.4M shares (10-Q, Nov 10, 2026) × $0.930 close Nov 17, 2026

Most recent annual filing: 2026-01-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Tranche A-1 warrants corporate updateJan 2027Tranche A-1 warrants corporate update, Jan 2027, routine
  2. KIO-401 corporate update2027KIO-401 corporate update, 2027, routine
  3. KIO-301 topline3Q 2027KIO-301 topline, 3Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

Ion Channel Modulator

Novel ion channel modulator platform with membrane-calming effects; primary focus on retinal disease (reducing pathological retinal hyperactivity); exploratory expansion into neurological disorders including epilepsy where neuronal hyperexcitability is implicated

Discontinued (2)

Capital (as filed)

Cash
$5.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$10.7M Sep 30, 2026
Operating cash flow
−$558K quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$16.3M cash, runway late 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Kiora Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Kiora Pharmaceuticals (KPRX): Scientific Deep Dive for KIO-301 and Pipeline Products Elegant photoswitch chemistry with TOI-funded clinical cost risk, but N=6 open-label data leaves efficacy a coin toss until double-masked ABACUS-2 RCT data arrives.
  2. Watch UPDATE: Kiora Pharmaceuticals (KPRX) - A 12-Month Delay, a $4.6M Impairment, and the Value of Deep-Pocketed Partners A 12-month delay to Q3 2027 ABACUS-2 data ties up capital longer, but TOI continues to fund KIO-301 R&D and the balance sheet remains intact into late 2027; no urgency to buy.
  3. Speculative buy speculative UPDATE: KIORA PHARMACEUTICALS INC (KPRX) - Perceptive Shows Up, Nature Medicine Prints, and the Warrant Structure Tells You the Plan Perceptive Advisors' at-market anchor investment, Nature Medicine publication of ABACUS-1, and a contractual strategic-transaction mandate shift the calculus enough to start a position on dips below $2.00.
  4. Speculative buy speculative UPDATE: Kiora Pharmaceuticals (KPRX) - The Runway Stretches, and a Catalyst Quietly Moves Up Runway extended to late 2028, ABACUS-2 high-dose cohort underway, and KLARITY readout pulled into late 2026 shortens the wait on the wholly-owned asset while Théa continues to fund KIO-301.
  5. Speculative buy speculative UPDATE: Kiora Pharmaceuticals (KPRX) - The Last Map Pin Gets Filled South Korea license completes the global partner map and a coordinated single global Phase 3 is now on record, while internal focus shifts to wholly-owned KIO-104 with a late-2026 readout.
  6. Speculative buy speculative UPDATE: Kiora Pharmaceuticals (KPRX) - They Hired the Phase 3 Guy Hiring a 12-global-Phase-3 veteran as EVP of Global Clinical Development closes the CDO succession gap and signals intent to architect the coordinated global Phase 3 plan.
  7. Watch UPDATE: Kiora Pharmaceuticals (KPRX) - The Pivot to Eye Stroke In-licensing self-funded Phase 3 KIO-401, killing KIO-104, and announcing a raise flips the outsourced-cost-risk model; wait for financing terms before re-entering.
  8. Avoid UPDATE: Kiora Pharmaceuticals (KPRX) - Going Concern, and a Warrant Clock Running Out of the Money Going-concern warning, runway guide that excludes a $12.5M Senju obligation, Tranche A-1 warrants expiring out-of-the-money, and a dilutive raise still unpriced make the risk/reward unfavorable.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)